Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092006 | 0.82 | MEN1 (0.53) | KMT2AMEN1SMN1; SMN2ALDH1A1CSNK2A1 | |
| SCHEMBL31369141 | 0.81 | LMNA (0.50) | NFE2L2KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL286054 | 0.81 | LMNA (0.50) | NFE2L2KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL9420260 | 0.81 | NFE2L2 (0.55) | NFE2L2KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL107259 | 0.79 | CSNK2A1 (0.59) | NFE2L2KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL30679777 | 0.79 | CSNK2A1 (0.59) | NFE2L2KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL501730 | 0.79 | NFE2L2 (0.49) | NFE2L2KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL29381894 | 0.79 | KMT2A (0.51) | NFE2L2KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL96218 | 0.79 | KMT2A (0.51) | NFE2L2KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL11300977 | 0.79 | TDP1 (0.46) | NFE2L2KMT2AMEN1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463647-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20180353475-A1 | Erythropoietin Expression Promoter | KAKE EDUCATIONAL INSTITUTION (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-2923700-B1 | ERYTHROPOIETIN EXPRESSION PROMOTER | UNIV TOHOKU (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| CN-104936591-B | Hematopoietin expression facilitator | 国立大学法人东北大学 | 2018-05-29 | — | — | CN | disclosed |
| US-20150353489-A1 | Erythropoietin Expression Promoter | KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2923700-A1 | ERYTHROPOIETIN EXPRESSION PROMOTER | Tohoku University (JP) | 2015-09-30 | — | — | EP | disclosed |
| CN-104936591-A | Erythropoietin expression promoter | UNIV TOHOKU NAT UNIV CORP | 2015-09-23 | — | — | CN | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-0444844-B1 | New 15-dehydroxy-16-oxoprostaglandins | R TECH UENO LTD (JP) | 1995-01-18 | — | — | EP | disclosed |
| US-5346921-A | Treatment of inflammation with 15-keto-prostaglandin compounds | R-TECH UENO, LTD. (JP) | 1994-09-13 | — | — | US | disclosed |
| US-5252605-A | Promotion of wound-healing with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| US-5221799-A | New 15-dehydroxy-16-oxoprostaglandins | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1993-06-22 | — | — | US | disclosed |
| US-5212324-A | TREATMENT OF CATARACT WITH 15-KETO-PROSTAGLANDIN COMPOUNDS | R.-TECH UENO LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| EP-0503887-A2 | Promotion of wound-healing with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0467564-A2 | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| EP-0453127-A2 | Treatment of cataract with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0444844-A2 | New 15-dehydroxy-16-oxoprostaglandins | R-TECH UENO LTD. (JP) | 1991-09-04 | — | — | EP | disclosed |
| US-3971825-A | (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS | SANKYO COMPANY LIMITED (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353475-A1 | Erythropoietin Expression Promoter | EPOR, NFE2L2, FOXO1 | NFE2L2 2/4885KMT2A 3254/4885MEN1 3086/4885 |
| US-20150353489-A1 | Erythropoietin Expression Promoter | EPOR, NFE2L2, FOXO1 | NFE2L2 2/4885KMT2A 3254/4885MEN1 3086/4885 |
| US-10004718-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | NFE2L2 2/4885KMT2A 3254/4885MEN1 3086/4885 |
| US-10463647-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | NFE2L2 2/4885KMT2A 3254/4885MEN1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.